Current stage-Stage IV Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Tucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain

Tucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain

Posted by on Jun 14, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases (BM) with tucatinib (Tukysa) plus trastuzumab (Herceptin) and capecitabine (Xeloda). This study found that this treatment reduces the risk of cancer worsening in these...

Read More

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

Posted by on May 24, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) treatment in older patients with colorectal cancer (CRC). Researchers suggested that this treatment has similar effects in younger and older patients. Some background CRC is the third most common cancer worldwide. More than half are diagnosed in patients older...

Read More

Bevacizumab combined with chemotherapy improves the outcomes of elderly patients with advanced colorectal cancer

Posted by on May 6, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of bevacizumab (Avastin) combined with chemotherapy in elderly patients with advanced colorectal cancer. Researchers suggested that this therapy might be associated with improved outcomes in fit older patients. Some background Colorectal cancer is the third most common cancer...

Read More

FOLFOXIRI plus bevacizumab improve the outcomes of patients with advanced colorectal cancer

Posted by on Apr 25, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared two different types of chemotherapy for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) is associated with better outcomes in these patients. Some background Colorectal cancer is the third most common cancer...

Read More

What are the long-term effects of treatment with a biological drug versus chemotherapy for patients with advanced non-small cell lung carcinoma?

Posted by on Mar 29, 2020 in Lung cancer | 0 comments

In a nutshell This study compared the long-term effects of biological drug pembrolizumab (Keytruda) with chemotherapy drug docetaxel (Taxotere) in patients with advanced non-small cell lung carcinoma (NSCLC). The study found that pembrolizumab increased survival and had fewer side effects than docetaxel. Some background Patients with advanced...

Read More

Cytoreductive surgery improves survival in patients with advanced colorectal cancer

Posted by on Mar 16, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of cytoreductive surgery (CRS) in patients with colorectal cancer spread to the peritoneum (inner lining of the abdominal cavity). Researchers suggested that CRS is associated with improved survival in these patients. Some background Colorectal cancer is the third most common cancer worldwide. A...

Read More

Adding ramucirumab to erlotinib treatment for patients with advanced non-small cell lung cancer with EGFR mutations

Posted by on Dec 20, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using two kinds of medication together worked better than only one medication to treat advanced non-small cell lung cancer that has not been treated before. The study found that using ramucirumab (Cyramza) with erlotinib (Tarceva) was better than using erlotinib alone. Some background There are a number...

Read More

Safety and effectiveness of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer

Posted by on Dec 17, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.  This study concluded that this combination was found to be safe and promising in these patients.  Some background Pembrolizumab (Keytruda) is a targeted...

Read More

High neutrophil-to-lymphocyte ratio in patients with melanoma treated with PD-1 inhibitor

Posted by on Dec 9, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out if a high neutrophil-to-lymphocyte ratio (NLR) was related to the survival of patients with melanoma treated with PD-1 inhibitor treatment. The study found that the higher the NLR, the lower the chances of survival in these patients.  Some background One type of melanoma treatment involves...

Read More

Radiation therapy after surgery improves survival of patients with advanced colon cancer

Posted by on Dec 8, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of radiation therapy (RT) after surgery in patients with T4 (cancer that has grown outside of the colon outer layer and invades the surrounding tissues) colon cancer. Researchers suggested that RT improved overall survival in these patients. Some background Colorectal cancer is the third...

Read More

Palbociclib and exemestane versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer

Posted by on Dec 7, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.  This study concluded that palbociclib and endocrine therapy is more effective than...

Read More

Evaluating the outcomes of patients with advanced melanoma with different treatments

Posted by on Dec 7, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out how well patients with advanced melanoma treated with certain medications survived outside of clinical trials. The study found that patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) or patients treated with anti-PD1 antibodies had longer survival compared to those treated with BRAF/MEK...

Read More